Gimv has completed its investment into the Apraxon Group, a leading homecare provider focusing on wound care services in Germany. This transaction is part of a joint growth plan with the company’s founder and CEO Oliver Pokrzewinski, who will continue to be an important shareholder in the company. 

Apraxon, (Hofbieber (DE) – apraxon.com), offers high quality wound care for (mostly elderly) people suffering from chronic wounds in a homecare setting. Typical wound indications include decubitus, diabetic foot or ulcus cruris. In providing this service, the company acts as an intermediary between patients, doctors, nursing services or homes and insurance companies.

Due to its high degree of specialization, Apraxon continuously provides high quality medical care and is able to tailor the treatment process according to each patient’s individual needs. In a market with steadily increasing patient numbers, primarily driven by demographic change, specialized medical care is gaining in importance. Services provided are reimbursed by health insurance companies, for whom Apraxon has been a reliable partner for many years.

“I am convinced that Gimv is the right partner to realize the company’s growth ambitions and expand Apraxon’s footprint in Germany,” explains Oliver Pokrzewinski, Managing Director and CEO of Apraxon. 

”Thanks to Apraxon’s clear commitment to quality, highly qualified nursing staff and strongly digitised and scalable processes, we believe that Apraxon is the right platform to build a true leader in the German wound care market. We are very much looking forward to supporting Mr. Pokrzewinski and the entire Apraxon team in realising their ambitious growth plans,” says Philipp v. Hammerstein, Partner at Gimv in the Health & Care team in Munich.

The new investment marks Gimv’s fifth acquisition in the German-speaking healthcare market over the last four years. Gimv currently has 23 participations in companies in the healthcare and life sciences sector. This acquisition further underpins Gimv’s position as one of the most active European investors in the healthcare industry and its ambition to positively contribute to the United Nations Sustainable Development Goals of good health and well-being. The Gimv portfolio also includes several clinic and practice groups, as well as medical technology and biotech companies